# OnCo record enfortumab-vedotin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/enfortumab-vedotin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "enfortumab-vedotin" ;
  schema:name "Enfortumab vedotin"@en ;
  schema:description "Enfortumab vedotin is an ADC against Nectin-4 that, combined with pembrolizumab, nearly doubled survival in advanced bladder cancer."@en ;
  schema:url <https://onco.cc/drugs/enfortumab-vedotin/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Enfortumab_vedotin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q19904068> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Enfortumab%20vedotin> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Padcev" ;
  onco:approval "US 2019: Advanced urothelial cancer after platinum and PD-1/PD-L1 (accelerated)", "US 2023: First-line advanced urothelial cancer with pembrolizumab", "EU 2022: mUC after platinum + PD-1; 1L with pembrolizumab 2024" ;
  onco:acceleratedApproval "US 2019-12-18: Adults with locally advanced or metastatic urothelial cancer who received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy in the neoadjuvant, locally advanced, or metastatic setting", "US 2023-04-03: In combination with pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy" ;
  onco:acceleratedApprovalConfirmed "US 2021-07-09: Adults with locally advanced or metastatic urothelial cancer who received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy in the neoadjuvant, locally advanced, or metastatic setting", "US 2023-12-15: In combination with pembrolizumab for the treatment of adult patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/muscle-invasive-bladder-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/nectin4/> ;
  onco:companies <https://onco.cc/companies/astellas/>, <https://onco.cc/companies/pfizer/> ;
  onco:terms <https://onco.cc/terms/mc-vc-pabc/> ;
  onco:trials <https://onco.cc/trials/ev-302/>, <https://onco.cc/trials/nct06483334/>, <https://onco.cc/trials/nct07815665/>, <https://onco.cc/trials/nct07720284/>, <https://onco.cc/trials/nct07475806/>, <https://onco.cc/trials/nct06305767/>, <https://onco.cc/trials/nct07421700/>, <https://onco.cc/trials/nct07566156/>, <https://onco.cc/trials/nct04225117/>, <https://onco.cc/trials/nct04960709/>, <https://onco.cc/trials/nct07287995/>, <https://onco.cc/trials/nct06493552/> .